Johnson & Johnson’s quarterly profit rises 3.3 percent

Johnson & Johnson reported a 3.3 percent rise in quarterly profit on Tuesday, as higher sales of cancer drugs Zytiga and Darzalex helped offset pressure on its blockbuster rheumatoid arthritis treatment Remicade.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News